Hypothesis

Renal organic anion transporters (OAT1/OAT3) competitively regulate the plasma clearance of indole-3-propionic acid (IPA) and uremic toxins such as indoxyl sulfate. The baseline serum IPA was lower in older adults with impaired versus normal renal function [1]. A polyphenol‑rich diet significantly increased serum IPA levels in older adults with normal renal function, with IPA variations correlating with C-reactive protein changes (β=0.32, p=0.010) and gut microbial orders including Clostridiales (r=0.35, p<0.001) [2]. Lower plasma IPA has been observed in humans with mild cognitive impairment and Alzheimer's disease [3]. IPA exhibits anti‑inflammatory and antioxidant effects and enhances gut barrier function [4]. IPA is consistently enriched in long-lived individuals and associated with healthier aging profiles [5]. When kidney function declines, increased tubular reabsorption of indoxyl sulfate reduces IPA efflux, lowering circulating IPA independent of gut microbial production. This creates a threshold effect: only when the IPA‑to‑indoxyl‑sulfate ratio exceeds a critical value does IPA activate hepatic AhR and Nrf2 pathways sufficiently to suppress inflammasome signaling and preserve gut barrier integrity. Consequently, IPA’s association with biological age and mortality is observable only in individuals with preserved renal function, explaining the failure of unstratified cohort studies to replicate IPA as a longevity biomarker.

Testable Predictions

1. In older adults with chronic kidney disease (CKD) stages 3‑5, oral IPA supplementation will fail to raise serum IPA unless co‑administered with an OAT inhibitor (e.g., probenecid) or dialysis that lowers indoxyl sulfate. Measuring the change in serum IPA after supplementation will show a significant interaction between baseline eGFR and IPA increment (p<0.01).

2. The plasma IPA‑to‑indoxyl‑sulfate ratio will predict all‑cause mortality and frailty progression better than IPA alone in longitudinal cohorts. A Cox model adding the ratio as a covariate will yield a hazard ratio of at least 0.70 per standard deviation increase, independent of CRP and traditional risk factors.

3. In vitro, human proximal tubular cells exposed to physiologic concentrations of indoxyl sulfate will demonstrate decreased IPA uptake via OAT1/OAT3 (measured by radiolabeled IPA) and increased intracellular oxidative stress, which can be rescued by OAT knockdown or by overexpressing Nrf2.

Mechanistic Rationale

The gut microbiota generates IPA from tryptophan, but hepatic AhR activation by IPA depends on its free plasma concentration. Uremic solutes such as indoxyl sulfate share structural similarity with IPA and are transported by the same OATs. Accumulation of these solutes in CKD competitively inhibits IPA secretion, effectively trapping IPA inside tubular cells where it undergoes efflux back into the lumen or is metabolized. Reduced plasma IPA diminishes AhR‑driven transcription of anti‑oxidant enzymes (HO‑1, NQO1) and weakens Nrf2‑mediated gut barrier reinforcement, permitting endotoxin translocation and systemic inflammation. This mechanistic chain links renal aging to a loss of IPA’s geroprotective signaling, providing a plausible explanation for why cross‑sectional enrichment of IPA in centenarians disappears when renal impairment is prevalent.

Implications

If validated, this hypothesis redirects biomarker development from measuring IPA alone to assessing the IPA‑to‑indoxyl‑sulfate ratio or directly evaluating OAT activity. It also suggests that therapeutic strategies targeting renal tubular transporters—or reducing indoxyl sulfate load—could restore IPA’s longevity‑promoting effects in aging populations with compromised kidney function.